Documents
Application Sponsors
Marketing Status
Application Products
001 | POWDER FOR ORAL SOLUTION | 1.5MG | 0 | EVRYSDI | RISDIPLAM |
FDA Submissions
TYPE 1; Type 1 - New Molecular Entity | ORIG | 1 | AP | 2020-08-07 | PRIORITY |
EFFICACY; Efficacy | SUPPL | 3 | AP | 2022-05-27 | STANDARD |
EFFICACY; Efficacy | SUPPL | 5 | AP | 2022-05-27 | PRIORITY |
LABELING; Labeling | SUPPL | 6 | TA | 2022-03-21 | STANDARD |
Submissions Property Types
ORIG | 1 | Null | 10 |
SUPPL | 3 | Null | 7 |
SUPPL | 5 | Null | 15 |
SUPPL | 6 | Null | 15 |
CDER Filings
GENENTECH INC
cder:Array
(
[0] => Array
(
[ApplNo] => 213535
[companyName] => GENENTECH INC
[docInserts] => ["",""]
[products] => [{"drugName":"EVRYSDI","activeIngredients":"RISDIPLAM","strength":"1.5MG","dosageForm":"POWDER FOR ORAL SOLUTION","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
[labels] => [{"actionDate":"08\/07\/2020","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/213535s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"08\/07\/2020","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 1 - New Molecular Entity","reviewPriority":"PRIORITY; Orphan","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/213535s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/213535Orig1s000ltr.pdf\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2020-08-07
)
)